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The child behavior checklist–dysregulation profile (CBCL–DP) refers to a pattern of
elevated scores on the attention problems, aggression, and anxiety/depression subscales
of the child behavior checklist. The aim of the present study was to investigate the
potential role of GABA inhibitory neurons in children with attention deficit/hyperactivity
disorder (ADHD) and dysregulation assessed with a dimensional measure. Brain single
photon emission computed tomography (SPECT) was performed in 35 children with
ADHD using 123I-iomazenil, which binds with high affinity to benzodiazepine receptors.
Iomazenil binding activities were assessed with respect to the presence or absence
of a threshold CBCL–DP (a score 210 for the sum of the three subscales: Attention
Problems, Aggression, and Anxiety/Depression). We then attempted to identify which
CBCL–DP subscale explained the most variance with respect to SPECT data, using
“age,” “sex,” and “history of maltreatment” as covariates. Significantly higher iomazenil
binding activity was seen in the posterior cingulate cortex (PCC) of ADHD children with
a significant CBCL–DP. The Anxiety/Depression subscale on the CBCL had significant
effects on higher iomazenil binding activity in the left superior frontal, middle frontal, and
temporal regions, as well as in the PCC. The present brain SPECT findings suggest
that GABAergic inhibitory neurons may play an important role in the neurobiology of the
CBCL–DP, in children with ADHD.
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Introduction
Severe behavioral and affective dysregulation with symptoms, such as hyperactivity, aggression,
irritability, mood instability, and anxiety, contribute to significant academic and psychosocial
impairment in children. Some of these symptoms are consistent with attention deficit hyperactivity
disorder (ADHD). ADHD is the most frequent neuropsychiatric disorder in children and often
presents with co-occurring disruptive behavior disorders, anxiety disorders, and bipolar disorder.
Hyperactivity, irritability, and impulsivity place children at risk of maltreatment as a result of
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strained parent–child interactions (1, 2). The insecure par-
ent–child relationship further exacerbates the behavioral and
affective dysregulation observed in children.
The child behavior checklist-dysregulation profile (CBCL–DP)
refers to a pattern of elevated scores on the Attention Prob-
lems, Aggression, and Anxiety/Depression subscales of the child
behavior checklist (CBCL) (3). The CBCL–DP was originally
proposed as a means of identifying youth with bipolar disor-
der (4). However, recent studies suggest that the results of the
CBCL–DP are not simply an earlymanifestation of a single disease
process, but rather that the CBCL–DP can be used as a devel-
opmental risk marker for a persisting deficit in self-regulation
of affect and behavior (5, 6). The CBCL–DP may be best inter-
preted as an indicator of symptom severity and functional impair-
ment (7, 8). Children with ADHD who had a threshold level
CBCL–DP score (210) showed higher rates of comorbidity dis-
orders, including oppositional defiant disorder (ODD), conduct
disorder (CD), anxiety disorder, bipolar disorder, and depres-
sion (9). The CBCL–DP is also associated with mood, anxiety,
disruptive behavior disorders, and substance use in adulthood (3).
The underlying neurobiological defects or aberrant neuronal
activity leading to the dysregulation profile in children with
ADHD are elusive. Reducing serotoninergic function in children
with ADHD and a significant CBCL–DP resulted in slower cogni-
tive performance compared to children with ADHD who did not
have the CBCL–DP, indicating that serotoninergic function could
play a decisive role in the etiology of the CBCL–DP (10). In addi-
tion, the CBCL subscale of “Aggression” was found to be the main
discriminator of ADHD children with CBCL–DP versus those
without CBCL–DP with respect to serotoninergic dysfunction.
Conversely, prior translational work with magnetic resonance
spectroscopy and transcanial magnetic stimulation paradigms
suggest that GABAergic neurochemistry and neurotransmission
are dysregulated in children with ADHD (11). Ongoing work also
suggests that defects in the GABAergic system in adults increase
an individual’s vulnerability to severe psychiatric illnesses due to
aberrant regulation of serotoninergic and/or dopaminergic neu-
rons (12, 13). Previous biochemical and pharmacological studies
indicate that deficits in GABA receptor function, induced by
intravenous infusion of iomazenil followed by a serotoninergic
agonist, predispose healthy volunteers to increased anxiety and
dissociative disturbances, suggesting that deficits in the GABAer-
gic system may contribute to the pathophysiology of serotonin-
induced psychosis (12).
123I-iomazenil is a radioactive ligand for central-type benzodi-
azepine receptors that forms a complex with GABA(A) receptors.
Thus, 123I-iomazenil single photon emission computed tomogra-
phy (SPECT) can indirectly index GABA receptor function. 123I-
iomazenil is a frequently used radionuclide tracer for presurgical
evaluation of patients with refractory partial epilepsy (14, 15).
Moreover, recent neuroimaging studies have explored the role
of GABAergic inhibitory function in psychiatric disorders such
as schizophrenia, anxiety disorders, and developmental disorders
(16–20). To our knowledge, there is no previous work which
characterizes GABA receptor functioning with 123I-iomazenil
SPECT among children with ADHD. The working hypothesis
of the present study was that behavioral and affective symptoms
in children with ADHD, reflected in CBCL–DP scores, would
correlate with changes in cortical GABAergic neuronal activity. To
confirm this hypothesis, brain SPECT was performed using 123I-
iomazenil in ADHD children with or without CBCL–DP. Further,
we tried to identify which of the three significant scales in the
CBCL–DP explains the most variance with respect to SPECT data
using “age,” “sex,” and “history of maltreatment” as covariates.
Materials and Methods
Ethics Statement
The design of the study and procedures for obtaining informed
consent were approved by the Medical Ethics Committee of
Kurume University School of Medicine (#10081). Informed con-
sent was obtained from each child and his/her parents prior to
their participation in the study.
Participants
Thirty-five children with ADHD (23 boys, 12 girls) enrolled in the
study. Participants were recruited after visits from theDepartment
of Pediatrics, Kurume University, for the management of exter-
nalizing symptoms (e.g., difficulty maintaining attention, rest-
lessness, hyperactivity, and aggressive behavior) or internalizing
symptoms (e.g., anxiety, dissociation, and depressive symptoms).
A diagnosis of ADHD was made using the Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th Edition, Text Revision
(Dsm-Iv-Tr) (21). Children who had anxious or depressive symp-
toms, but did not have ADHD symptoms were excluded in this
study. Of the 35 child participants with ADHD, 15 had the com-
bined type, 11 had hyperactive-impulsive type, and 9 had inatten-
tive type. Seventeen children (7male, 10 females) had experienced
an obvious maltreatment, such as physical (n= 9), psychological
(n= 6), or sexual abuse (n= 1), or sexual assault (n= 1) during
preschool. In 11 of these instances, a child-welfare consultation
center had previously supported the families in hopes of prevent-
ing maltreatment. Two children stayed in a child residential care
institution. However, none of the participants met the diagnostic
criteria for posttraumatic stress disorder (PTSD) on assessment.
Seven of the 35 subjects (20%) had comorbid disorders, such as
ODD(n= 2), CD (n= 1), anxiety disorder (n= 2), and depression
(n= 2). The mean age of the children at the time of their hospital
visit was 10.4 years. All participants were medication naïve prior
to enrollment.
Child Behavior Checklist
Behavioral and psychiatric assessments of the children included
the CBCL, ADHD rating scale (hyperactivity/impulsive and inat-
tention scores, as well as total score) (22, 23), the ChildDepression
Inventory (CDI), the Child Dissociative Checklist (CDC), and the
Wechsler Intelligence Scale for Children (WISC-III). The CBCL
was used to evaluate children’s emotional and behavioral func-
tioning, competencies, and social problems, with specific items
evaluating internalizing and externalizing symptoms, as well as
attention and thought problems. Items evaluating internalizing
symptoms focus on withdrawal, somatic complaints, and anx-
iety/depression. Items evaluating externalizing symptoms focus
on delinquent or aggressive behavior. The CBCL–DP refers to
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a pattern of elevated scores on the Attention Problems, Aggres-
sion, and Anxiety/Depression subscales of the CBCL. A threshold
CBCL–DP was defined as a score 210 for the sum of three
subscales. (4) Physicians rated the participants using the ADHD
rating scale, CDI, and CDC, and the parents rated their children
using the CBCL.
Iomazenil Single Photon Emission Computed
Tomography and Analysis of Regions of Interest
All 35 children underwent iomazenil SPECT imaging of the
brain. Briefly, children were injected intravenously with a bolus
of 95–117MBq 123I-iomazenil (Nihon Medi-Physics, Tokyo,
Japan), which binds with high affinity to benzodiazepine recep-
tors. The SPECT scan was performed 3 h after injection of
the tracer, without any sedation, using a large field-of-view
dual-detector camera and a computer system equipped with a
low-energy, high-resolution, parallel-hole collimator. The dual
detector camera rotated over 180° in a circular orbit and in 32
steps of 40 s each to cover 360° in about 22min. Brain magnetic
resonance imaging (MRI) was performed using a superconduct-
ing magnet operating at 1.5 T. For coregistered SPECT and MRI
analysis, a method of image integration was applied using Fusion
Viewer software (Nihon Medi-Physics) with a registration algo-
rithm based on maximummutual information (Figure 1). Subse-
quently, the cortical and subcortical regions of interest (ROIs) in
the acquired SPECT data were defined. Using elliptical templates,
the ROIs were placed over the following regions: the superior
frontal, middle frontal, parietal, temporal, and occipital regions
in each hemisphere; the midbrain; and the anterior and posterior
cingulate cortex (ACC and PCC, respectively; Figure 1). Each
relative iomazenil binding activity in ROIs was expressed as a
ratio of that in the occipital cortex. As 123I-iomazenil affinity in
the occipital region was maximum and stable in brain cortex, the
occipital region was used as a reference (24).
Data Analysis
The differences of each CBCL subscale, ADHD-RS, CDI score,
CDC score, and Intelligence scale between ADHD children
with/without CBCL–DP were compared by student’s t-test. We
first analyzed correlations between the relative iomazenil bind-
ing activity expressed as a ratio in each ROI and psychometric
profiles after controlling for the effects of age, sex, and history of
maltreatment. Further, we compared iomazenil binding activity
with respect to the presence or absence of a threshold CBCL–DP
score in these children and tried to identify which of the three
CBCL–DP subscales explained the most variance with respect
to the SPECT data. Associations between each of the CBCL–DP
subscales and iomazenil binding activity in each brain area were
evaluated using liner regression models, with “age,” “sex,” and
“history of maltreatment” as covariates.
Results
Behavioral and psychiatric assessments of the participants were
shown in Table 1. Of the 35 participants, 15 had a threshold
CBCL–DP score (i.e., a score210) and 20 had CBCL–DP scores
<210. The group with threshold CBCL–DP scores had a lower
FIGURE 1 | Designated regions of interest (ROIs) in fusion images of
123I-iomazenil SPECT and MRI. The top panel shows brain MRI
(transverse and sagittal T1 sequences), the middle panel shows
corresponding results of 123I-iomazenil SPECT, and the bottom panel shows
fusion imaging. Outlined regions in the bottom panel indicate designated
ROIs, namely (a) the superior frontal, (b) parietal, (c) middle frontal,
(d) temporal, (e) occipital regions, (f) anterior, and (g) posterior cingulate gyrus.
ratio of male to female participants and more instances of mal-
treatment. Each ADHD rating scale, all subscales of CBCL with
the exception of somatic problems, and CDC score were sig-
nificantly higher in ADHD children with threshold CBCL–DP
scores. Four participants with threshold level CBCL–DP scores
had comorbidity disorders, including depression (n= 2), ODD
(n= 1), and CD (n= 1). Three participants without threshold
CBCL–DP scores had comorbidity disorders, including anxiety
disorder (n= 2) and ODD (n= 1). There was a difference in the
CBCL–DP scores between participants with/without comorbid-
ity disorders; however, this difference did not reach statistical
significance (n= 28, 199 20, and n= 7, 209 12, respectively,
p= 0.10).
Analyses of all participants (n= 35) revealed correlations
between iomazenil binding activity in several brain regions and
some part of the CBCL profile, after controlling for the effects of
age, sex, and a history ofmaltreatment (Table 2). In bothACC and
PCC, iomazenil binding activity had a statistically significant pos-
itive correlation with scores on the Anxiety/Depressed (Table 2;
Figure 2), Internalizing, and Withdrawal Problems subscales of
the CBCL (Table 2). In addition, significant positive correlations
were noted for iomazenil binding activity in theACCandThought
Problems on the CBCL, as well as for iomazenil binding activity
in the PCC and Attention problems and Social Problems on the
CBCL (Table 2). These significant correlations were not seen for
other combinations in other brain regions, except for iomazenil
binding activity in the midbrain and Thought Problems on the
CBCL, and iomazenil binding activity in the right temporal region
and Social Problems on the CBCL. There were no significant cor-
relations between iomazenil binding activities in any brain region
and any of the ADHD rating scales, CDI score, and CDC score
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TABLE 1 | Behavioral and psychiatric assessments of participants.
ADHD children
without significant
CBCL–DP
ADHD children
with significant
CBCL–DP
Number of participants 20 15
Male:Female 173 6 9
Mean age (years) 10:7 1:9 10:0 1:8
Experience of maltreatment (%) 40 80
ADHD-RS
Total score 23:5 9:2 30:6 9:0*
Inattention score 14:8 5:7 17:9 4:9*
Impulsivity/hyperactivity score 9:2 5:6 12:6 6:0*
CBCL score
Internalizing score 64:4 9:7 80:8 8:2**
Externalizing score 62:7 8:5 71:1 4:8**
Aggressive behaviors 63:7 9:0 79:2 7:2**
Anxious/depressed 58:1 4:9 66:4 4:5**
Attention problem 66:2 5:4 73:7 5:5**
Delinquent behavior 62:7 8:5 71:1 4:8**
Withdrawn 61:5 5:6 66:3 5:6**
Somatic problems 55:5 15:2 58:4 9:5
Social problems 62:0 8:8 66:9 8:1*
Thought problems 59:9 9:7 67:8 9:9*
CDI score 14:3 9:6 15:6 6:3
CDC score 6:7 3:8 13:3 4:7**
WISC-III 90:0 15:6 87:3 13:7
CBCL–DP, child behavior checklist–dysregulation profile; ADHD-RS, attention deficit
hyperactivity disorder rating scale; CDI, child depression inventor; CDC, children disso-
ciative checklist; WISC, Wechsler intelligence scale for children.
Significant difference from children without significant CBCL–DP (*indicates p<0.05,
**indicates p< 0.001).
(data not shown). Iomazenil binding activity in the PCC was sig-
nificantly higher in ADHD children with a threshold CBCL–DP
score than in ADHD children with scores <210 after controlling
for the effects of age, sex, and a history of maltreatment (Table 3,
F-value= 4.36, p< 0.05). Of the three CBCL–DP subscales, the
Anxiety/Depression subscale had significant effects on higher
iomazenil binding activity in the left superior frontal, middle
frontal, and temporal regions, as well as in the PCC (Table 4).
Discussion
This is the first neuroimaging study showing that behavioral
and affective symptoms in children with ADHD, reflected
in CBCL–DP scores, are correlated with changes in cortical
GABAergic neuronal activity. Overall, increased iomazenil
activity in the ACC and PCC was associated with higher scores
on many of the CBCL subscales. In ADHD children with a
significant CBCL–DP, iomazenil activity was upregulated in the
PCC. Of the three CBCL–DP subscales, the Anxiety/Depression
subscale had a significant effect on iomazenil binding activity
in many brain regions. These results suggest that behavioral and
affective dysregulation in ADHD children may be characterized
by changes of GABAergic neural activity. In this section, we
discuss the role of the cingulate cortex in GABA function, the
association between CBCL–DP scores and GABA function, and
age-dependent differences in GABA function.
The cingulate cortex is one of the largest parts of the limbic
lobe and the prefronto-limbic circuitry. The ACC plays key roles
in emotion, motivation, and motor functions, whereas the PCC
is involved in emotion, facial recognition, and memory functions
(25–27). In the present study, we found higher iomazenil binding
activity inACC and PCC that was associatedwith higher scores on
many of the CBCL subscales in ADHD children with and without
CBCL–DP. Similar findings have been reported in healthy adults.
For example, Kim et al. (28) found a positive correlation in healthy
subjects between high GABA concentrations in the ACC and a
high harm avoidance temperament, characterized by worrying
about potential problems, fearful of uncertainties, and being shy
in unfamiliar environments. Moreover, increased activity in the
PCC has been observed in emotional disorders, including obses-
sive–compulsive disorder, major depression, and social phobia
(29, 30). Because the cingulate cortex has been suggested to have
an important role in modulating human fear and anxiety by
modulating the activity of other limbic structures, including the
amygdala (31), the increased GABAergic function in the cingulate
cortex of ADHD children in the present study may have inhibited
excessive excitation of the limbic system, which contributes to the
development of behavioral and affective dysregulation.
We found that the Anxiety/Depression subscale of the
CBCL–DP explains the most variance with respect to SPECT
data in various brain regions using “age,” “sex,” and “history
of maltreatment” as covariates. The Aggression and Attention
Problem subscales of the CBCL–DP had no significant effects
on SPECT data in various brain regions. These findings strongly
support previous converging lines of evidence regarding the
association between GABAergic activation and increased anxiety
(32). Conversely, several biochemical and genetic studies have
provided evidence of a significant role of serotoninergic function
in aggressive behavior. For example, an inverse correlation
has been reported between downregulated platelet or CSF
5-hydroxyindolecetic acid (5-HIAA), a major metabolite of
serotonin, and levels of aggression and impulsivity (33, 34). Fur-
thermore, Haberstick et al. (35) reported an association between
certain promoter polymorphisms in the serotonin transporter
(5HTTLPR) and greater aggressive behavior inmiddle childhood,
suggesting that differences in serotonergic functioning may be
a contributing factor to different levels of aggressive behavior.
In terms of the biological mechanism underlying attention
function, an important role for dopaminergic neurons has been
proposed. Several neuroimaging studies have shown aberrant
dopamine transporter (DAT) levels in the nucleus accumbens,
caudate, and midbrain, as well as a positive relationship between
DAT levels in the putamen and inattention scores in ADHD
patients (36–38). Together, these findings suggest that changes
in several neurotransmitter systems, including serotoninergic,
dopaminergic, and GABAergic neurons, are likely to be involved
in constructing the clinical manifestations of the CBCL–DP.
Significant positive correlations betweenGABAergic inhibitory
function and the Anxiety/Depression subscale were also seen
in our study. Although previous neuroimaging studies have
reported those correlations in adulthood with psychiatric disor-
ders (17, 28), the present study is the first report of the correla-
tion in childhood with psychiatric disorders. Despite the positive
correlation in childhood, previous neuroimaging studies using
iomazenil SPECT have revealed negative correlations between
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TABLE 2 | Partial correlation coefficients between CBCL profiles and the iomazenil binding activites in each brain region.
Superior frontal Parietal Middle frontal Temporal Mid brain ACC PCC
R L R L R L R L
CBCL profiles
Total problems 0:341 0.237 0:192 0.267 0:301 0:229 0:284 0:191 0:178 0:385 0:245
Internalizing problems 0:199 0.160 0:026 0.068 0:110 0:188 0:136 0:332 0:274 0:477* 0:536**
Externalizing problems 0:158 0.086 0:057 0.090 0:148 0:027 0:127  0:072 0:032 0:078  0:041
Aggressive behaviorsa 0:119 0.052 0:036 0.077 0:113  0:042 0:088  0:111  0:040 0:017  0:026
Anxious/depresseda 0:309 0.284 0:120 0.129 0:264 0:335 0:246 0:369 0:355 0:536** 0:524**
Attention problema 0:265 0.120 0:234 0.157 0:228 0:166 0:248 0:160 0:212 0:378 0:483**
Delinquent behavior 0:122 0.091 0:068 0.102 0:133 0:087 0:175 0:108 0:159 0:077 0:008
Withdrawn 0:278 0.105 0:163 0.006 0:192 0:057 0:338 0:214  0:012 0:425* 0:509**
Somatic problems  0:131 0.045  0:162 0.035  0:133 0:074  0:246 0:080 0:216  0:050 0:205
Social problems 0:304 0.112 0:325 0.217 0:264 0:108 0:406* 0:204 0:129 0:383 0:440*
Thought problems 0:322 0.221 0:269 0.207 0:307 0:320 0:310 0:239 0:546** 0:432* 0:360
CBCL, child behavior checklist; ACC, anterior cingulate cortex; PCC, posterior cingulate cortex; R, right; L, left.
*Indicates p< 0.05; **indicates p<0.01.
a Indicates subscale which comprises CBCL–DP (dysregulation profile).
FIGURE 2 | Correlations between iomazenil binding activity in the
anterior and posterior cingulate cortices and score of subscale
CBCL anxiety/depressed in all subjects. The higher relative iomazenil
binding activities in ACC and PCC are significantly associated with the higher
scores of “Anxiety/Depressed” subscale in the CBCL. CBCL, child behavior
checklist.
TABLE 3 | Effect of the significant CBCL–DP (score 210) on iomazenil
binding activities in each brain region.
Brain area Effect F-Test p-Value
Right superior frontal Significant CBCL–DP 0:88 0:35
Left superior frontal Significant CBCL–DP 0:18 0:67
Right parietal Significant CBCL–DP 2:07 0:16
Left parietal Significant CBCL–DP 0:37 0:55
Right middle frontal Significant CBCL–DP 1:57 0:22
Left middle frontal Significant CBCL–DP 0:44 0:51
Right temporal Significant CBCL–DP 1:26 0:27
Left temporal Significant CBCL–DP 0:05 0:82
Midbrain Significant CBCL–DP 0:2 0:66
Anterior cingulate cortex Significant CBCL–DP 0:99 0:33
Posterior cingulate cortex Significant CBCL–DP 4:36 <0:05
CBCL–DP, child behavior checklist–dysregulation profile.
GABA–benzodiazepine receptor binding activity and the severity
of anxiety symptoms in adults with panic or traumatic disorders
(17–19). It is well known that there are considerable changes
in the number of GABA receptors and in subunit expression
during brain development (39). Specifically, the greatest number
of GABA receptors is found in the youngest children, with num-
bers decreasing exponentially with age, and there are age-related
increases in α1-subunit-containing GABA receptors (40). These
age-related changes inGABA receptorsmay affect outcomeswhen
assessing increases and/or decreases in overall iomazenil binding
activity in children.
The present study has several limitations that require con-
sideration in future studies. For example, in the present study,
SPECT exhibited poor resolution around some limbic regions,
such as the amygdala and hippocampus, which are important
for emotion processing. In these small regions, the obtained
radioactivity might differ from the true activity because of partial
volume effect (PVE). The PVE can be defined as the under-
estimation of binding per unit brain volume in small objects
or regions because of the blurring of the radioactivity (spill-
out and spill-in) between regions. These regions need to be
resolved using MR imaging-based correction for PVE (41, 42).
Brain imaging data from normal healthy children are not available
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TABLE 4 | Effect of the CBCL–DP subscale on iomazenil binding activities
in each brain region.
Brain area Effect F-Test p-Value
Right superior frontal Aggressive behavior 0:03 0.8708
Anxious/depressed 2:79 0.1058
Attention problem 0:12 0.7268
Left superior frontal Aggressive behavior 0:01 0.9374
Anxious/depressed 4:28 0.0479*
Attention problem 1:6 0.2157
Right parietal Aggressive behavior 0 0.9675
Anxious/depressed 0:13 0.7249
Attention problem 0:39 0.5367
Left parietal Aggressive behavior 0:33 0.5703
Anxious/depressed 0:67 0.4214
Attention problem 0:02 0.8843
Right middle frontal Aggressive behavior 0 0.9771
Anxious/depressed 1:83 0.1871
Attention problem 0:06 0.8060
Left middle frontal Aggressive behavior 0:5 0.4873
Anxious/depressed 5:1 0.0319*
Attention problem 0:92 0.3457
Right temporal Aggressive behavior 0:03 0.8709
Anxious/depressed 1:46 0.2363
Attention problem 0:02 0.8888
Left temporal Aggressive behavior 0:12 0.7354
Anxious/depressed 7:55 0.0104*
Attention problem 1:91 0.1777
Mid brain Aggressive behavior 0:66 0.4231
Anxious/depressed 1:98 0.1699
Attention problem 0:21 0.6482
Anterior cingulate cortex Aggressive behavior 0:97 0.3331
Anxious/depressed 3:94 0.0570
Attention problem 1:06 0.3118
Posterior cingulate cortex Aggressive behavior 0:99 0.3277
Anxious/depressed 5:62 0.0248*
Attention problem 1:26 0.2714
CBCL–DP, child behavior checklist–dysregulation profile.
*Indicates significant effects on higher iomazenil binding activity.
because of ethical concernswith SPECT studies of this population.
Therefore, we focused our research questions on the correlation
between GABAergic inhibitory function in specific brain regions
and psychometric profiles. It is possible that, in addition to the
population of people withADHD, our result is generalizable to the
normal population. Furthermore, we selected iomazenil activity
in the occipital regions as a reference, meaning that we could
not evaluate inhibitory function in occipital regions. We did not
clarify how putative dopaminergic or serotoninergic changes are
involved in other subscales, such as the Aggression and Attention
Problem subscales, of the CBCL–DP. It is possible that investi-
gations incorporating the simultaneous assessment of benzodi-
azepine receptor binding activity and homovanillic acid (HVA)
and 5HIAA in the urine (principal metabolites of dopamine
and serotonin, respectively) could provide new insights into the
underlying neurobiological defects or aberrant neuronal activity
leading to the dysregulation profile in children.
In conclusion, the present 123I-iomazenil brain SPECT study
provides evidence that changes in GABAergic inhibitory neuronal
activity correlate with some elements of function measured by the
CBCL–DP. Brain SPECT may be useful for the evaluation of the
possible pathogenesis of neuropsychiatric symptoms observed in
children.
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